The funds raised in this issue are mainly used for the acquisition of high-quality targets in the cardiovascular field and health protection field and the expansion of production capacity, and further expand the medium and low-value and high-value consumable products category of the company’s medical equipment industry.
On the evening of August 2, Lanfan Medical Co., Ltd. (hereinafter referred to as “Lanfan Medical”, 002382.SZ) disclosed that the company intends to publicly issue convertible corporate bonds (hereinafter referred to as “convertible bonds” The total amount of funds raised is not more than RMB 3.144 billion. It is intended to be used in the development of a series of projects of the company’s two business divisions, namely the Cardiovascular and Cardiovascular Division and the Protection Division.
The plan shows that funds raised in this issue are mainly used for the acquisition of high-quality targets in the cardiovascular field and health protection field and the expansion of production capacity, further expanding the medium and low-value and high-value consumable products of the company’s medical equipment industry. Category , including: acquisition of 100% equity and capital increase of interventional aortic valve company NVT AG, acquisition of 6.63% minority stake in CBCH II, and annual production of 2 billion health protection (new gloves) Annual production of 2 billion health-protected nitrile gloves technical transformation, acquisition of 100% equity of Wuhan Baker and repayment of bank loans and supplementary liquidity.
High Value Consumables: Nuggets TAVR Golden Circuit
It is reported that the main fund raised by Lanfan Medical, about 1.39 billion yuan, will be used to acquire and increase the capital of NVT (New Valve Technology), a Swiss-based transcatheter interventional heart valve R&D manufacturer.
The announcement shows that NVT’s main product is TAVR (transcatheter aortic valve replacement) implanted instrument – AllegraTM, which is mainly used to treat cardiac aortic valve related lesions. Compared with traditional treatments, TAVR products can deliver interventional instruments to the heart through blood vessels like PCI cardiac stent surgery. They have multiple advantages such as no need for thoracotomy, small trauma and quick recovery, and have achieved commercial success in the United States, Europe and Japan. Has been highly recognized by experts in cardiac interventional medicine.
According to Edwards Lifesciences, the global market for transcatheter heart valves in the year of 2018 is $3.5 billion, and will reach $7 billion in 2024. It is in a period of rapid growth and is the fastest growing gold circuit in the cardiovascular device field.
However, Due to the high technical content of the product, the difficulty of research and development, and the long cycle, the current TAVR device products are scarce. In this area, NVT is one of the only five major TAVR manufacturers to land in the European market (the other four are Edwards Life Sciences, Medtronic, Abbott, Boston Scientific).